JP2024516183A - Sos遺伝子発現を調節するための組成物及び方法 - Google Patents

Sos遺伝子発現を調節するための組成物及び方法 Download PDF

Info

Publication number
JP2024516183A
JP2024516183A JP2023565227A JP2023565227A JP2024516183A JP 2024516183 A JP2024516183 A JP 2024516183A JP 2023565227 A JP2023565227 A JP 2023565227A JP 2023565227 A JP2023565227 A JP 2023565227A JP 2024516183 A JP2024516183 A JP 2024516183A
Authority
JP
Japan
Prior art keywords
composition
antisense oligonucleotide
mrna
nucleic acid
sos1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516183A5 (cg-RX-API-DMAC10.html
Inventor
リーシャン チェン
ボハン ジン
Original Assignee
モレキュラー アクシオム エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー アクシオム エルエルシー filed Critical モレキュラー アクシオム エルエルシー
Publication of JP2024516183A publication Critical patent/JP2024516183A/ja
Publication of JP2024516183A5 publication Critical patent/JP2024516183A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023565227A 2021-04-22 2022-04-22 Sos遺伝子発現を調節するための組成物及び方法 Pending JP2024516183A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178420P 2021-04-22 2021-04-22
US63/178,420 2021-04-22
PCT/US2022/026052 WO2022226377A1 (en) 2021-04-22 2022-04-22 Compositions and methods for modulating sos gene expressions

Publications (2)

Publication Number Publication Date
JP2024516183A true JP2024516183A (ja) 2024-04-12
JP2024516183A5 JP2024516183A5 (cg-RX-API-DMAC10.html) 2025-04-30

Family

ID=83723199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565227A Pending JP2024516183A (ja) 2021-04-22 2022-04-22 Sos遺伝子発現を調節するための組成物及び方法

Country Status (6)

Country Link
US (1) US20240182894A1 (cg-RX-API-DMAC10.html)
EP (1) EP4326878A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024516183A (cg-RX-API-DMAC10.html)
KR (1) KR20240032184A (cg-RX-API-DMAC10.html)
CN (1) CN117751190A (cg-RX-API-DMAC10.html)
WO (1) WO2022226377A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4396349A4 (en) * 2021-09-02 2025-10-22 Molecular Axiom Llc COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION
JP2025521912A (ja) 2022-07-06 2025-07-10 モレキュラー アクシオム エルエルシー 膵臓癌を治療するための組成物及び方法
WO2024138135A2 (en) * 2022-12-22 2024-06-27 Molecular Axiom, Llc Compositions and methods for modulating sos gene expressions
WO2025111565A1 (en) * 2023-11-22 2025-05-30 Empirico Inc. Treatment of sos2 related diseases and disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070490A1 (en) * 2002-06-26 2005-03-31 Chiron Corporation Sos1 inhibitors
WO2010091308A2 (en) * 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US20110269820A1 (en) * 2010-04-28 2011-11-03 Iowa State University Research Foundation, Inc. Spinal muscular atrophy treatment via targeting smn2 catalytic core
JP2019525918A (ja) * 2016-07-15 2019-09-12 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. Smn2の調節のための化合物及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US7901882B2 (en) * 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
WO2014144148A1 (en) * 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
EP3169776B1 (en) * 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation
WO2016161153A2 (en) * 2015-04-01 2016-10-06 The Regents Of The University Of California Prognostic and diagnostic methods for colorectal cancer
JP2025521912A (ja) * 2022-07-06 2025-07-10 モレキュラー アクシオム エルエルシー 膵臓癌を治療するための組成物及び方法
WO2024138135A2 (en) * 2022-12-22 2024-06-27 Molecular Axiom, Llc Compositions and methods for modulating sos gene expressions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070490A1 (en) * 2002-06-26 2005-03-31 Chiron Corporation Sos1 inhibitors
WO2010091308A2 (en) * 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US20110269820A1 (en) * 2010-04-28 2011-11-03 Iowa State University Research Foundation, Inc. Spinal muscular atrophy treatment via targeting smn2 catalytic core
JP2019525918A (ja) * 2016-07-15 2019-09-12 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. Smn2の調節のための化合物及び方法

Also Published As

Publication number Publication date
EP4326878A1 (en) 2024-02-28
KR20240032184A (ko) 2024-03-11
EP4326878A4 (en) 2025-07-02
CN117751190A (zh) 2024-03-22
WO2022226377A1 (en) 2022-10-27
US20240182894A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
JP2023529316A (ja) ゲノム編集のための組成物及び方法
US11946050B2 (en) Polynucleotide compositions and methods for gene expression regulations
US20240182894A1 (en) Compositions and methods for modulating sos gene expressions
EP3484524B1 (en) Compounds and methods for modulation of smn2
JP2024532477A (ja) Kras発現を調節するための組成物及び方法
EP4689107A1 (en) Chemically modified antisense oligonucleotides for use in rna editing
WO2022269346A2 (en) Compositions and methods of modulating xanthine dehydrogenase
TW202104595A (zh) 用來調節dux4的表現之化合物、方法及醫藥組成物
US20250270550A1 (en) Cyclic Structured Oligonucleotides as Therapeutic Agents
US20260062703A1 (en) Delivery of RNA Therapeutics Using Circular Prodrug Nucleic Acids
WO2024138135A2 (en) Compositions and methods for modulating sos gene expressions
CN121399260A (zh) 用于治疗神经退行性疾病的反义寡核苷酸
JP2024532476A (ja) Nlrp3またはnlrp1発現を調節するための組成物及び方法
KR20250136379A (ko) Kras 발현을 조절하기 위한 조성물 및 이의 용도
CN118251494A (zh) 用于调节kras表达的组合物和方法
HK40113403A (en) Cyclic structured oligonucleotides as therapeutic agents
JP2026503426A (ja) 癌を処置するためのポリヌクレオチド組成物および方法
CN118613582A (zh) 工程化rna
HK40079272A (en) Compounds and methods useful for modulating gene splicing
CN114929336A (zh) 用于调节基因剪接的化合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260217

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20260417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260604